Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Comparing the Efficacy of Bevacizumab in Combination With Rituximab and CHOP (R-CHOP + Bevacizumab) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Comparing the Efficacy of Bevacizumab in Combination With Rituximab and CHOP (R-CHOP + Bevacizumab) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms MAIN
  • Sponsors Roche

    • Most Recent Events

    • 08 Dec 2020 Results of pooled analysis assessing (data from MAIN and GOYA studies) how lymphoma microenvironment may affect clinical outcome in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) receiving immunochemotherapypresented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2018 Results assessing cell of origin (COO) using genomic features from next generation targeted sequencing, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Dec 2015 Results of retrospective analysis presented at the 57th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top